The device isn't the product anymore. The procedure is.
No $1.5M capital robot. No implant lock-in. Value-based accountability in orthopedics is no longer voluntary — it's federal policy. MSKvalue assembles best-of-class musculoskeletal care into one accountable episode: personalize the surgery, measure the outcome, get paid on the value — pay-per-case, no capital wall.
For clinicians & ASCs → For patients →The buyer of surgical technology isn't a procurement manager with a CapEx budget anymore. It's the ASC operator watching procedure volume, the service-line leader tracking cost per case, and the CFO measuring reimbursement and ROI. So the evaluation metrics change:
| Stop evaluating on | Start evaluating on |
|---|---|
| Features | Cost per procedure |
| Specifications | Utilisation rate |
| Price per unit | Revenue per operating-room hour |
| The capital committee | Clinical outcomes, measured |
CMS has said the quiet part out loud: voluntary models let organizations opt in only when they can win. So the newest models are compulsory — and orthopedics is the tip of the spear.
Mandatory joint-replacement bundle (2026, ~740 hospitals). Hip & knee episodes scored on cost, complications, readmissions, and patient-reported outcomes through 30 days post-discharge. What an administrator does now →
Mandatory, no opt-out. The low-back cohort pulls orthopedic, spine, neurosurgery, and pain clinicians into peer benchmarking — with −9% to +9% of Part B riding on each individual clinician's cost-and-quality score. The ASM math →
Finalized July 31, 2026 (CMS-1849-F): mandatory joint-replacement bundles for most IPPS hospitals nationwide (TEAM participants, Maryland, and hospitals not paid under both IPPS and OPPS excepted). Hip, knee, and — newly — ankle, with 90-day episode accountability on total Part A+B spending and quality. The first expanded mandatory episode model in Medicare history. The model page at CMS →
A joint-replacement's cost isn't one number; it's four levers. MSKvalue pulls all four — and and the implant line is the biggest of them.
Performing TJR in a surgery center runs ~20–40% less* than the hospital setting — several thousand dollars saved per case*, with lower 90-day admissions and ED visits too.
The implant is ~50% of a TJR's total cost* — the single largest line. Standardizing to the construct the case actually needs, negotiated on cost rather than the rep’s catalog, attacks that line directly — without locking the facility to one manufacturer’s system. This is the metric that moves the story.
Revisions cost ~76% more* than the primary — and infection revisions run tens of thousands. Personalized alignment lowers revision risk, so the savings compound over years.
Camera-based recovery and remote monitoring cut readmissions inside the 30-day episode CMS now scores — protecting the bundle and adding RTM revenue.
arthritisrisk.com and jointclass.com publish independent patient education on joint health and what the evidence supports. They name no surgeon, no facility and no product, and nothing they publish depends on where a patient goes next.
Standard implants and mechanical alignment force every patient's joint into a narrow set of shapes. Real anatomy doesn't work that way. Here is the case for personalization, made plainly.
No two knees, hips, or shoulders are the same. A plan and implant matched to the individual restores their own anatomy instead of averaging it away.
Recent systematic reviews put residual dissatisfaction after knee replacement at roughly 7–10% (the honest range runs 5–20%, definition-dependent) — often tied to alignment and fit. Personalization is a direct answer to the residual-dissatisfaction problem.
Better fit targets lower revision risk — and revisions are the single biggest episode-cost driver (~76% more than the primary). Under mandatory two-sided risk, avoided revisions are savings the provider keeps.
Why your revision rate is your P&L →Implant-agnostic planning, delivered as software rather than steel. The weeks that can be taken out of a complex case are the design and iteration weeks — not the manufacturing weeks — and that is a meaningful share of an eight-to-sixteen-week cycle.
Honest framing: the high-level trial evidence on personalization is still maturing — which is exactly why the founding-surgeon model instruments every case and feeds the registry. The argument today is mechanistic, value-aligned, and patient-centered; the confirmatory data is what we build.
Component malposition drives revision, and the literature is consistent on it: glenoid and component placement accuracy is tied to clinical and radiographic outcome (Gregory, PLoS One 2013), and poor position is a recurring feature of unsatisfactory and revised arthroplasty (Franta, JSES 2007; Duethman, JSES Int 2020). In the shoulders that failed and required revision, most components were found malpositioned (Sperling, JSES 2025).
The honest boundary — and it is the point: that last figure is the rate among revisions, not the rate across all replacements. We say it precisely because vendors quote the revision number as if it were the general incidence. The defensible claim is narrower and stronger: position affects outcome, malposition drives the costly revisions the mandatory models now measure, and a plan built to the patient’s anatomy is the lever — on any implant, not one manufacturer’s.
Under TEAM, ASM, and now CJR-X, you are accountable for the whole episode — and paid on what you can document. Here is the record a value-based MSK program has to produce, stage by stage, on any implant and inside any surgeon’s workflow.
The prior-authorization trail and a functional baseline (PROMs, gait) that establish the patient genuinely needed surgery — the record payers and the mandate both require.
Whatever construct and alignment the surgeon chooses, the decision and its rationale are captured — a named clinician’s judgment, documented, never overwritten by a tool.
The two biggest episode levers — surgery-center versus hospital, and implant cost — captured per case, so the savings are provable rather than asserted.
PROMs and remote monitoring track the 30–90 day window CMS scores — RTM-qualifying data that both protects the bundle and is separately billable.
Every case fed to the American Joint Replacement Registry — the national standard the mandatory models measure you against.
Cost, complications, and outcomes documented end to end — the record that turns a mandate from a risk into a shared-savings return.
MSKvalue doesn't reinvent the wheel; it integrates the best product at each stage of the joint-care episode into a single, measured, reimbursable arc.
Free MSK risk screening turns a population into identified surgical candidates before they ever call. arthritisrisk →
Evidence-based pre-op and post-op education that scales the "best-in-class" patient experience. JointClass →
The surgeon’s construct and alignment choice captured per case — implant-agnostic, so the decision and its cost are provable on any system.
Every case instrumented and benchmarked against the American Joint Replacement Registry — 4.6M procedures, the national standard the mandatory models score you on. AJRR →
The AI practice OS — coding, prior auth, RTM, and 90-second AJRR abstraction — so the value you create is actually reimbursed. SurgeonValue →
Camera-based recovery tracking that generates RTM-qualifying adherence and functional-outcome data — closing the episode loop. JointCoach →
The path to a better joint now begins online — a symptom search, a free risk check, a night of reading — long before a patient ever chooses a surgeon. A patient who arrives at that consult already understanding what personalization is, and what the evidence supports, asks better questions and makes a more informed decision. These sites educate; they never route.
Knee or hip pain sends them online. A free joint check meets them there.
Plain-language education shows a plan built for their body is possible.
Independent education helps them understand the options and see which nearby surgeons offer personalized planning — they choose and contact directly. No routing, no introductions.
The demand arrives at the OR already asking for the personalized plan.
Traditional ortho marketing pays $150–600 per lead (fully loaded $1,000–3,000+) and only pays off if the patient converts to surgery — so the ~80% who don't need surgery are treated as wasted spend. The CMS ACCESS Model (musculoskeletal track, live July 2026) inverts that: managing chronic MSK pain is itself reimbursed, so the whole screened population is cared for, not filtered for the few who reach the OR.
ACCESS pays outcome-aligned and co-management fees (code G0677) for managing chronic MSK pain. The ~80% of screened patients who don't need surgery become recurring, reimbursed enrollees — not lost acquisition cost.
CMS Innovation Center →The ~200 ACCESS participant organizations already serve attributed Medicare panels. Offering those patients independent MSK education and a free risk check (arthritisrisk.com) is care delivered inside a relationship that already exists — not cold Google and Meta spend, and not a referral to anyone in particular.
arthritisrisk →A minority of people screened will need surgery, and they arrive at that consult understanding what the options are and what the evidence supports. We measure whether the education worked, not where anyone went.
Where the patients come from →Figures illustrative and directional; ACCESS payment is outcome-aligned and structure-dependent. These sites educate and screen — they do not refer patients to any specific surgeon, facility, or product. Any arrangement that touches referrals is structured with counsel (AKS/FMV). Not legal or financial advice.
You're now accountable for cost, complications, and outcomes on every joint-replacement episode. MSKvalue is the operating system that lets you land on the right side of the peer curve.
A better joint replacement isn't a bigger hospital. It's a plan built for your anatomy, a team that measures how you actually recover, and care that stays with you from the first ache to full function.
A free check on your joint health.
Know what to expect, before & after.
A plan built for your anatomy.
Guided recovery, tracked at home.
Under mandatory two-sided risk, better alignment and fewer revisions stop being a cost and become a return the accountable provider keeps. Illustrative.
Surgeon, ASC, health system, or industry partner — leave your details and we'll follow up directly with what's relevant to your side of the value-based episode. No newsletter, no spam.